AR
CELG

Advisory Research’s Celgene Corp CELG Stock Holding History

Advisory Research’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,642
Closed -$239K – 465
2017
Q3 		$239K Buy
+1,642
New +$224K ﹤0.01% 409
2014
Q2 		– Sell
-862
Closed -$60K – 798
2014
Q1 		$60K Buy
+862
New +$68.3K ﹤0.01% 761

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Advisory Research's CELG Position: Q4 2017 in Review

Advisory Research sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 1,642 shares — an estimated $239K sold.

Advisory Research first reported a position in CELG in Q1 2014 and held it in 2 quarters. The position peaked at $239K in Q3 2017. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • Advisory Research reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
  • Advisory Research sold 1,642 Celgene Corp shares in Q4 2017, an estimated $239K.
  • Advisory Research first reported a position in Celgene Corp in Q1 2014 and held it in 2 quarters.
  • Advisory Research's Celgene Corp position peaked at $239K in Q3 2017.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Advisory Research's 13F filing for Q4 2017, filed 8 Feb 2018.